News | Peripheral Artery Disease (PAD) | August 27, 2019

New Report Says Concept Medical Positioned to Disrupt Peripheral Market

Analysis by GlobalData says company poised to take market share from major device manufacturers following FDA Breakthrough Therapy Designation

New Report Says Concept Medical Positioned to Disrupt Peripheral Market

August 27, 2019 — Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for below-the-knee (BTK) use of its MagicTouch drug-coated balloon catheter (DCB) for the treatment of peripheral artery disease (PAD). The company is now in a position to potentially disrupt this market and become a threat to larger manufacturers that have an established presence in the peripheral space, according to data and analytics company GlobalData.

In the U.S., there are currently three FDA-approved drug-coated balloons for treating above-the-knee PAD: Medtronic’s In.Pact Admiral, Becton Dickinson’s Lutonix and Philips’ Stellarex.

Sheryl Tang, senior medical devices analyst at GlobalData, commented, “Despite the heightened caution surrounding paclitaxel-coated devices, there is still a large unmet need for BTK DCB interventions for high-risk patients who may require the benefits of drug-coated devices such as limiting the blockage or re-growth of plaques post-intervention, thereby limiting the need for re-intervention.”

Companies are racing to enter and monopolize the U.S. BTK DCB market, recognizing that it is a market with great potential and no current competition.

Tang continued, “If Concept Medical is the first company to receive approval for BTK DCB use, it would not only monopolize the large untapped market, but could potentially steal market share from Medtronic, Philips and Becton Dickinson in the DCB space.”

Additionally, with a new type of balloon on the market for patients with BTK PAD, Concept Medical could take a portion of the patient pool that is currently only treated with regular balloons, taking market share from major manufacturers in that space as well. However, as it is a smaller company in a market dominated by major manufacturers with large device portfolios, Concept Medical will also be a target for acquisition.

For more information:

Related Content

Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score Percutaneous Transluminal Angioplasty (PTA) Scoring Sheath platform for use in iliac, ilio-femoral, popliteal, infra-popliteal and renal arterial plus synthetic and/or native arteriovenous hemodialysis fistula. This is a new type of scoring balloon technology.
News | Balloon Catheter | June 04, 2020
June 4, 2020 — Transit Scientific announced the U.S.
NC Trek RX Coronary Dilatation Catheter is part of an FDA Class I recall because it may not defalte.
News | Balloon Catheter | February 24, 2020
February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters
Edwards Lifesciences Recalls IntraClude Intra-aortic Occlusion Device
News | Balloon Catheter | July 15, 2019
Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon rupture during...
Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...